Clinical Trial

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

Study acronym: PANDA
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-08-14; most recent amendment 2026-07-17.
Status change: Recruiting → Active, Not Recruiting 2025-12-11
Status change: Not Yet Recruiting → Recruiting 2025-09-23
Trial Details
NCT Number NCT07128615
Lead Sponsor AstraZeneca
Collaborators: Biomedical Advanced Research and Development Authority, Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies
Conditions Influenza A
Enrollment 405 participants
Start Date 2025-09-04
Primary Completion 2026-01-28 (estimated)
Study Completion 2026-12-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-20